Patents Assigned to Alkermes
  • Fusion Polypeptides Comprising Mucin-Domain Polypeptide Linkers
    Publication number: 20130336925
    Abstract: The invention provides fusion proteins having improved bioactivity comprising a first polypeptide fusion partner and a second polypeptide fusion partner wherein the first fusion partner is linked to the second fusion partner by a mucin-domain polypeptide linker and wherein the bioactivity of the fusion protein of the invention is improved as compared to fusion of the first polypeptide fusion partner and the second polypeptide fusion partner in the absence of the mucin-domain polypeptide linker. Mucin-domain polypeptide linkers comprise a mucin domain that is rich in potential glycosylation sites, and has a high content of serine and/or threonine and proline, which can represent greater than 40% of the amino acids within the mucin domain and further comprise at least about 60% of its mass due to the glycans.
    Type: Application
    Filed: June 6, 2013
    Publication date: December 19, 2013
    Applicant: Alkermes, Inc.
    Inventors: JUAN ALVAREZ, LESLIE A. MCSWEENEY
  • Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
    Patent number: 8592427
    Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: November 26, 2013
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Laura Cook Blumberg, Julius F. Remenar, Örn Almarsson, Tarek A. Zeidan
  • Injectable Nanoparticulate Olanzapine Formulations
    Publication number: 20130309310
    Abstract: Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine.
    Type: Application
    Filed: July 24, 2013
    Publication date: November 21, 2013
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Stephen B. Ruddy, David Czekai, Gary Liversidge, Scott A. Jenkins, Elaine M. Liversidge
  • Process for synthesizing oxidized lactam compounds
    Patent number: 8536328
    Abstract: The invention provides a method for the synthesis of dehydrogenated lactam drugs of Formula I:
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: September 17, 2013
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Julius F. Remenar, Laura Cook Blumberg, Tarek A. Zeidan
  • NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
    Publication number: 20130224123
    Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.
    Type: Application
    Filed: December 4, 2012
    Publication date: August 29, 2013
    Applicant: Alkermes Pharma Ireland Limited
    Inventor: Alkermes Pharma Ireland Limited
  • Nanoparticulate meloxicam formulations
    Patent number: 8512727
    Abstract: The present invention is directed to nanoparticulate compositions comprising meloxicam. The meloxicam particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: August 20, 2013
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Eugene R. Cooper, Tuula Ryde, John Pruitt, Laura Kline
  • COMPOSITIONS OF BUPRENORPHINE AND µ ANTAGONISTS
    Publication number: 20130190342
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.
    Type: Application
    Filed: December 14, 2012
    Publication date: July 25, 2013
    Applicant: Alkermes Pharma Ireland Limited
    Inventor: Alkermes Pharma Ireland Limited
  • Prodrugs of Secondary Amine Compounds
    Publication number: 20130184265
    Abstract: The present invention relates to compounds of Formula I:
    Type: Application
    Filed: December 14, 2012
    Publication date: July 18, 2013
    Applicant: Alkermes Pharma Ireland Limited
    Inventor: Alkermes Pharma Ireland Limited
  • Polymer-based sustained release device
    Patent number: 8461105
    Abstract: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: June 11, 2013
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Steven G. Wright, Troy Christensen, Thean Yeoh, Michael E. Rickey, Joyce M. Hotz, Rajesh Kumar, Henry R. Costantino
  • POLYMER-BASED SUSTAINED RELEASE DEVICE
    Publication number: 20130130977
    Abstract: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
    Type: Application
    Filed: January 16, 2013
    Publication date: May 23, 2013
    Applicants: Amylin Pharmaceuticals, LLC, Alkermes Pharma Ireland limited
    Inventors: Alkermes Pharma Ireland Limited, Amylin Pharmaceuticals, LLC
  • Heterocyclic compounds for the treatment of neurological and psychological disorders
    Patent number: 8431576
    Abstract: Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: April 30, 2013
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Julius F. Remenar, Laura Cook Blumberg, Tarek A. Zeidan
  • Polymer-based sustained release device
    Patent number: 8431685
    Abstract: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
    Type: Grant
    Filed: February 25, 2010
    Date of Patent: April 30, 2013
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Steven G. Wright, Troy Christensen, Thean Yeoh, Michael E. Rickey, Joyce M. Hotz, Rajesh Kumar, Henry R. Costantino
  • METHODS FOR ADMINISTERING ARIPIPRAZOLE
    Publication number: 20130090343
    Abstract: The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.
    Type: Application
    Filed: October 10, 2012
    Publication date: April 11, 2013
    Applicant: Alkermes, Inc.
    Inventor: Alkermes, Inc.
  • Polymorphic forms of naltrexone
    Patent number: 8389540
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: September 25, 2007
    Date of Patent: March 5, 2013
    Assignee: Alkermes, Inc.
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20130045276
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: August 14, 2012
    Publication date: February 21, 2013
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • Nanoparticulate carverdilol formulations
    Patent number: 8367112
    Abstract: The present invention is directed to nanoparticulate carvedilol compositions having improved pharmacokinetic profiles, improved bioavailability, dissolution rates and efficacy. In one embodiment, the nanoparticulate carvedilol composition has an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: February 5, 2013
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Gary Liversidge, Scott Jenkins
  • Drug delivery device
    Patent number: 8361028
    Abstract: A drug delivery device having a housing containing a gas generator controlled by an electronic controller. The gas generator generates gas into a reciprocable chamber, whereby reciprocation of the chamber causes a lever to reciprocate a pawl, and this action causes a ratchet to undergo incremental advancement. The device may also be provided with manual control for delivering a bolus dose of drug when necessary.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: January 29, 2013
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Joseph Gross, Izrail Tsals, Gilad Lavi, Gil Yigal, Ehoud Carmel
  • Drug delivery device
    Patent number: 8361027
    Abstract: A drug delivery device having a housing containing a gas generator controlled by an electronic controller. The gas generator generates gas into a reciprocable chamber, whereby reciprocation of the chamber causes a lever to reciprocate a pawl, and this action causes a ratchet to undergo incremental advancement. The device may also be provided with manually control for delivering a bolus dose of drug when necessary.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: January 29, 2013
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Joseph Gross, Izrail Tsals, Gilad Lavi, Gil Yigal, Ehoud Carmel
  • Selective opioid compounds
    Patent number: 8354534
    Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to morphinan compounds useful as ?, ?, and/or ? receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: January 15, 2013
    Assignee: Alkermes, Inc.
    Inventors: Derrick Arnelle, Daniel Deaver, Reginald L. Dean, III, Mark Todtenkopf
  • DRUG DELIVERY DEVICE
    Publication number: 20130012875
    Abstract: A drug delivery device having a housing containing a gas generator controlled by an electronic controller. The gas generator generates gas into a reciprocable chamber, whereby reciprocation of the chamber causes a lever to reciprocate a pawl, and this action causes a ratchet to The device may also be provided with manually control for delivering a bolus dose of drug when necessary.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Joseph Gross, Izrail Tsals, Gilad Lavi, Gil Yigal, Ehoud Carmel